Roth Capital Has Positive Estimate for CELZ FY2024 Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Equities researchers at Roth Capital boosted their FY2024 earnings estimates for shares of Creative Medical Technology in a note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($3.19) for the year, up from their previous forecast of ($3.29). The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q4 2024 earnings at ($0.63) EPS, FY2025 earnings at ($2.24) EPS, FY2026 earnings at ($2.66) EPS, FY2027 earnings at $3.26 EPS and FY2028 earnings at $6.34 EPS.

Creative Medical Technology Stock Performance

Shares of NASDAQ:CELZ opened at $2.50 on Monday. The company has a 50 day moving average price of $3.46 and a two-hundred day moving average price of $3.68. The company has a market capitalization of $4.37 million, a PE ratio of -0.71 and a beta of 2.01. Creative Medical Technology has a 52 week low of $2.48 and a 52 week high of $10.28.

Institutional Trading of Creative Medical Technology

A hedge fund recently raised its stake in Creative Medical Technology stock. Aaron Wealth Advisors LLC raised its holdings in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,570 shares of the company’s stock after acquiring an additional 3,170 shares during the period. Aaron Wealth Advisors LLC owned about 1.45% of Creative Medical Technology worth $75,000 as of its most recent filing with the Securities and Exchange Commission. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.